|
Lipid
Disorders in Treatment-naive HIV Patients Using Lopinavir/Ritonavir-based
HAART
The
aim of this study was to evaluate the frequency, characteristics
and risk factors of lipid
changes associated with lopinavir/ritonavir
(Kaletra) treatment in antiretroviral-naive patients.
A prospective cohort of 107 antiretroviral-naive HIV-infected patients
was followed for 12 months after starting lopinavir/ritonavir-based
HAART.
Results
· At
12 months, percentages of patients with hypercholesterolaemia
and hypertriglyceridaemia
were 17.4% and 40%, respectively.
· Mean
increases in total cholesterol and triglycerides were 40.7 and 73.3
mg/dL.
· There
was a significant increase in both low-density and high-density
(HDL) cholesterol, and no increase in the total cholesterol/HDL
ratio (from 4.16 at baseline to 4.49 after 12 months).
· Baseline
cholesterol > 200 mg/dL and triglycerides > 150 mg/dL were
independent risk factors for dyslipidaemia,
while hepatitis C coinfection appeared to be protective.
The
authors conclude, “Patients with elevated lipid values at baseline
have the greatest risk of developing hypercholesterolaemia and hypertriglyceridaemia
after starting lopinavir/ritonavir. Antiretroviral-naive patients coinfected
with hepatitis C have a low risk of developing hyperlipidaemia
after starting lopinavir/ritonavir.”
Internal Medicine Service, La Paz Hospital,
Autonoma University School of Medicine, Madrid, Spain.
03/25/05
Reference
M
L Montes and others. Lipid disorders in antiretroviral-naive patients
treated with lopinavir/ritonavir-based HAART: frequency, characterization
and risk factors. Journal of Antimicrobial Chemotherapy.
March 10, 2005. [Epub ahead of print]
|
